High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA1801R73" target="_blank" >RIV/61988987:17110/17:A1801R73 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/17:00097567 RIV/65269705:_____/17:00067158 RIV/00843989:_____/17:E0106426

Result on the web

<a href="http://dx.doi.org/10.1371/journal.pone.0181487" target="_blank" >http://dx.doi.org/10.1371/journal.pone.0181487</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1371/journal.pone.0181487" target="_blank" >10.1371/journal.pone.0181487</a>

Result language

angličtina

Original language name

High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma

Original language description

Introduction: Multiple myeloma (MM) is still incurable due to resistance against various therapies. Thus, the identification of biomarkers predicting progression is urgently needed. Here, we evaluated four biomarkers in bone marrow and peripheral blood of MM patients for their prognostic significance. Materials & methods: Bone marrow- and peripheral blood plasma levels of FLT3-L, soluble TIE2, endostatin, and osteoactivin were determined in patients with monoclonal gammopathy of undetermined significance (MGUS, n = 14/n = 4), patients with newly diagnosed MM (NDMM, n = 42/n = 31) and patients with relapsed/refractory MM (RRMM, n = 27/n = 16) by sandwich ELISA. Results: Median FLT3-L expression increased from MGUS (58.77 pg/ml in bone marrow; 80.40 pg/ ml in peripheral blood) to NDMM (63.15 pg/ml in bone marrow; 85.05 pg/ml in peripheral blood) and was maximal in RRMM (122 pg/ml in bone marrow; 160.47 pg/ml in peripheral blood; NDMM vs. RRMM p&lt;0.001). A cut-off value of FLT3-L &gt;92 pg/ml in bone marrow and &gt;121 pg/ml in peripheral blood was associated with relapse or refractoriness in MM patients. FLT3-L was found to be a high predictive marker for discrimination between NDMM and RRMM as well in bone marrow as in peripheral blood (AUC 0.75 in bone marrow; vs 0.84 in peripheral blood). Conclusion: High levels of FLT3-L in bone marrow and peripheral blood of MM patients identify patients with progressive disease and are associated with relapse or refractoriness in MM patients. FLT3-L could be useful as a marker to identify RRMM patients and should be evaluated as target for future therapies. &#169; 2017 Steiner et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

PLOS ONE

ISSN

1932-6203

e-ISSN

—

Volume of the periodical

12

Issue of the periodical within the volume

7

Country of publishing house

US - UNITED STATES

Number of pages

14

Pages from-to

—

UT code for WoS article

000406634500078

EID of the result in the Scopus database

2-s2.0-85024894808